Harvard Bioscience Zukünftiges Wachstum
Future Kriterienprüfungen 0/6
Harvard Bioscience wird ein jährliches Gewinn- und Umsatzwachstum von 106.7% bzw. 9.3% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 107.4% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 4.7% betragen.
Wichtige Informationen
83.0%
Wachstumsrate der Gewinne
84.5%
EPS-Wachstumsrate
| Life Sciences Gewinnwachstum | 18.1% |
| Wachstumsrate der Einnahmen | 7.8% |
| Zukünftige Eigenkapitalrendite | -0.2% |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 09 Aug 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Harvard Bioscience (NASDAQ:HBIO) Is Making Moderate Use Of Debt
Aug 07
Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares Not Telling The Full Story
Jul 15Even With A 25% Surge, Cautious Investors Are Not Rewarding Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Performance Completely
Dec 22Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Intrinsic Value Is Potentially 60% Above Its Share Price
Sep 23Harvard Bioscience, Inc. (NASDAQ:HBIO) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Aug 10An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 23% Undervalued
Apr 26Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Afford Some Debt
Apr 11Harvard Bioscience GAAP EPS of $0.05 beats by $0.06, revenue of $29.2M misses by $1.2M
Aug 04Harvard Bioscience (NASDAQ:HBIO) Takes On Some Risk With Its Use Of Debt
Jun 08Harvard Bioscience - Dressed Up And Waiting For A Suitor
Mar 15Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Manage Its Debt Responsibly
Feb 16Is Harvard Bioscience (NASDAQ:HBIO) Using Too Much Debt?
Nov 04Is Harvard Bioscience, Inc. (NASDAQ:HBIO) Trading At A 37% Discount?
Oct 01An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 25% Undervalued
May 04These 4 Measures Indicate That Harvard Bioscience (NASDAQ:HBIO) Is Using Debt Extensively
Apr 19Analysts Are Optimistic We'll See A Profit From Harvard Bioscience, Inc. (NASDAQ:HBIO)
Apr 04Have Insiders Sold Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Recently?
Mar 20What Kind Of Shareholders Hold The Majority In Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares?
Mar 07Harvard Bioscience (NASDAQ:HBIO) Shareholders Have Enjoyed A 92% Share Price Gain
Feb 17An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 35% Undervalued
Feb 02
Have Insiders Been Buying Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares This Year?
Jan 15Harvard Bioscience: Wait For The Green Shoots Of Improvement
Jan 12When Will Harvard Bioscience, Inc. (NASDAQ:HBIO) Become Profitable?
Dec 28Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 123 | 2 | 8 | 12 | 1 |
| 12/31/2025 | 107 | -3 | 4 | 7 | 2 |
| 12/31/2024 | 98 | -11 | -2 | 1 | 2 |
| 6/30/2024 | 101 | -11 | 6 | 9 | N/A |
| 3/31/2024 | 107 | -9 | 11 | 14 | N/A |
| 12/31/2023 | 112 | -3 | 12 | 14 | N/A |
| 9/30/2023 | 113 | -3 | 11 | 12 | N/A |
| 6/30/2023 | 114 | -5 | 7 | 9 | N/A |
| 3/31/2023 | 115 | -2 | 4 | 5 | N/A |
| 12/31/2022 | 113 | -10 | 0 | 1 | N/A |
| 9/30/2022 | 118 | -7 | -3 | -1 | N/A |
| 6/30/2022 | 121 | -4 | -4 | -3 | N/A |
| 3/31/2022 | 121 | -6 | -3 | -2 | N/A |
| 12/31/2021 | 119 | 0 | 0 | 1 | N/A |
| 9/30/2021 | 117 | -2 | 2 | 4 | N/A |
| 6/30/2021 | 111 | -3 | 5 | 6 | N/A |
| 3/31/2021 | 105 | -4 | 6 | 7 | N/A |
| 12/31/2020 | 102 | -8 | 8 | 9 | N/A |
| 9/30/2020 | 102 | -7 | 8 | 9 | N/A |
| 6/30/2020 | 105 | -8 | 9 | 11 | N/A |
| 3/31/2020 | 112 | -7 | 8 | 9 | N/A |
| 12/31/2019 | 116 | -5 | 7 | 8 | N/A |
| 9/30/2019 | 119 | -2 | 8 | 8 | N/A |
| 6/30/2019 | 120 | 0 | 3 | 4 | N/A |
| 3/31/2019 | 122 | -1 | 4 | 4 | N/A |
| 12/31/2018 | 121 | -4 | 2 | 3 | N/A |
| 9/30/2018 | 109 | -8 | -2 | -1 | N/A |
| 6/30/2018 | 99 | -8 | 2 | 3 | N/A |
| 3/31/2018 | 86 | -7 | N/A | 2 | N/A |
| 12/31/2017 | 77 | -2 | N/A | 1 | N/A |
| 9/30/2017 | 82 | -3 | N/A | 4 | N/A |
| 6/30/2017 | 88 | -4 | N/A | 5 | N/A |
| 3/31/2017 | 96 | -4 | N/A | 5 | N/A |
| 12/31/2016 | 105 | -4 | N/A | 5 | N/A |
| 9/30/2016 | 106 | -20 | N/A | 5 | N/A |
| 6/30/2016 | 107 | -19 | N/A | 2 | N/A |
| 3/31/2016 | 110 | -18 | N/A | 0 | N/A |
| 12/31/2015 | 109 | -19 | N/A | 1 | N/A |
| 9/30/2015 | 111 | -2 | N/A | 0 | N/A |
| 6/30/2015 | 110 | 0 | N/A | 1 | N/A |
| 3/31/2015 | 109 | 0 | N/A | 3 | N/A |
| 12/31/2014 | 109 | 2 | N/A | 4 | N/A |
| 9/30/2014 | 106 | 2 | N/A | 4 | N/A |
| 6/30/2014 | 106 | 1 | N/A | 5 | N/A |
| 3/31/2014 | 105 | 1 | N/A | 5 | N/A |
| 12/31/2013 | 105 | 1 | N/A | 4 | N/A |
| 9/30/2013 | 106 | 4 | N/A | 4 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: HBIO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Ertrag vs. Markt: HBIO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Hohe Wachstumserträge: HBIO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Einnahmen vs. Markt: HBIODie Einnahmen des Unternehmens (7.8% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.6% pro Jahr).
Hohe Wachstumseinnahmen: HBIODie Einnahmen des Unternehmens (9.3% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: HBIO wird voraussichtlich in 3 Jahren unrentabel sein.